MCID: HRT032
MIFTS: 78

Heart Disease

Categories: Cardiovascular diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Heart Disease

MalaCards integrated aliases for Heart Disease:

Name: Heart Disease 12 6 15 17
Congenital Heart Disease 12 29 55 6 15 17 72
Heart Failure 55 6 43 63 17 72 33
Congenital Heart Defects 12 29 6 43 3 63
Heart Diseases 55 43 44 15 72
Congenital Anomaly of Heart 12
Disease, Heart, Congenital 40
Congenital Heart Disorder 75
Heart Defects, Congenital 44
Heart Disease, Congenital 40
Congestive Heart Failure 72
Heart Defects Congenital 55
Congenital Heart Defect 12
Heart-Congenital Defect 12
Heart Malformation 12
Heart Defects 15
Heart Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:114 DOID:1682
ICD9CM 35 429.9 746.9
NCIt 50 C3079 C34666
SNOMED-CT 68 13213009 56265001
UMLS 72 C0018798 C0018799 C0018801 more

Summaries for Heart Disease

MedlinePlus : 43 If you're like most people, you think that heart disease is a problem for others. But heart disease is the number one killer in the U.S. It is also a major cause of disability. There are many different forms of heart disease. The most common cause of heart disease is narrowing or blockage of the coronary arteries, the blood vessels that supply blood to the heart itself. This is called coronary artery disease and happens slowly over time. It's the major reason people have heart attacks. Other kinds of heart problems may happen to the valves in the heart, or the heart may not pump well and cause heart failure. Some people are born with heart disease. You can help reduce your risk of heart disease by taking steps to control factors that put you at greater risk: Control your blood pressure Lower your cholesterol Don't smoke Get enough exercise NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Heart Disease, also known as congenital heart disease, is related to dilated cardiomyopathy and ventricular septal defect, and has symptoms including tremor, angina pectoris and edema. An important gene associated with Heart Disease is GATA4 (GATA Binding Protein 4), and among its related pathways/superpathways are Cardiac conduction and MicroRNAs in cancer. The drugs Citalopram and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial.

CDC : 3 Congenital heart defects (CHDs) are conditions that are present at birth and can affect the structure of a baby's heart and the way it works. They are the most common type of birth defect. As medical care and treatment have advanced, infants with congenital heart defects are living longer and healthier lives. Many now are living into adulthood.

PubMed Health : 63 About congenital heart defects: Congenital (kon-JEN-ih-tal) heart defects are problems with the heart's structure that are present at birth. These defects can involve:

Wikipedia : 75 A congenital heart defect (CHD), also known as a congenital heart anomaly and congenital heart disease,... more...

Related Diseases for Heart Disease

Diseases in the Heart Disease family:

Congenital Heart Defects, Multiple Types, 6 Congenital Heart Defects, Multiple Types, 3
Congenital Heart Defects, Multiple Types, 2 Congenital Heart Defects, Multiple Types, 4
Congenital Heart Defects, Multiple Types, 5

Diseases related to Heart Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2720)
# Related Disease Score Top Affiliating Genes
1 dilated cardiomyopathy 34.2 TBX5 RYR2 NPPB NKX2-5 MYH6 GATA4
2 ventricular septal defect 34.0 TBX5 NPPB NKX2-5 GATA4
3 patent ductus arteriosus 1 33.8 NPPB NKX2-5 GATA4
4 hypoplastic left heart syndrome 33.6 NPPB NKX2-5 MYH6
5 aortic valve disease 1 33.4 NPPB NKX2-5 H19
6 holt-oram syndrome 33.4 TBX5 NKX2-5 MYH6
7 heart septal defect 33.3 TBX5 NKX2-5 GATA4
8 atrioventricular block 33.2 TBX5 NPPB NKX2-5 GATA4
9 atrial heart septal defect 33.1 TBX5 NKX2-5 MYH6 GATA4
10 tetralogy of fallot 33.1 TBX5 NPPB NKX2-5 GATA4
11 atrial standstill 1 32.9 NPPB MYH6 MIR320A
12 congestive heart failure 32.7 NRON NPPB MYH6 MT-LIPCAR MIR214 MIR21
13 patent foramen ovale 32.5 TBX5 NKX2-5 MYH6 GATA4
14 atrioventricular septal defect 32.5 TBX5 NKX2-5 GATA4
15 myocardial infarction 32.4 NPPB MT-LIPCAR MIR210 MIR21 GATA4
16 ebstein anomaly 32.2 NPPB NKX2-5 GATA4
17 pulmonary valve disease 32.2 TBX5 GATA4
18 left ventricular noncompaction 32.2 RYR2 NKX2-5 MYH6 MHRT
19 heart, malformation of 31.1 TBX5 MYH6
20 dermatomyositis 30.9 MIR214 MIR210 MIR21
21 polymyositis 30.8 MIR214 MIR210 MIR21
22 muscular dystrophy, duchenne type 30.7 MIR214 MIR210 MIR21
23 leukemia, acute lymphoblastic 30.7 MIR210 MIR21 ABL1
24 inclusion body myositis 30.3 MIR214 MIR21 BACE1-AS
25 leukemia, acute myeloid 30.2 MIR320A MIR210 MIR21 HOTAIR ABL1
26 diffuse large b-cell lymphoma 29.8 MIR320A MIR210 MIR21 HOTAIR
27 kidney cancer 29.6 MIR214 MIR210 MIR21 HOTAIR H19
28 ovarian cancer 29.6 MIR214 MIR210 MIR21 HOTAIR H19 BACE1-AS
29 coronary heart disease 1 12.8
30 deafness, congenital heart defects, and posterior embryotoxon 12.7
31 short stature, developmental delay, and congenital heart defects 12.7
32 congenital heart defects, multiple types, 3 12.7
33 congenital heart defects, dysmorphic facial features, and intellectual developmental disorder 12.7
34 congenital heart defects, multiple types, 4 12.7
35 multiple joint dislocations, short stature, and craniofacial dysmorphism with or without congenital heart defects 12.7
36 congenital heart defects and ectodermal dysplasia 12.6
37 hypertensive heart disease 12.6
38 rheumatic heart disease 12.5
39 coronary heart disease 5 12.5
40 coronary heart disease 6 12.5
41 coronary heart disease 7 12.5
42 pulmonary arterial hypertension associated with congenital heart disease 12.4
43 structural heart defects and renal anomalies syndrome 12.4
44 ectrodactyly of lower limbs, congenital heart defect, and micrognathia 12.4
45 cleft lip and palate-craniofacial dysmorphism-congenital heart defect-hearing loss syndrome 12.4
46 kyphoscoliotic heart disease 12.4
47 critical congenital heart disease 12.4
48 testicular anomalies with or without congenital heart disease 12.4
49 brachydactyly-mesomelia-intellectual disability-heart defects syndrome 12.4
50 coloboma, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies syndrome 12.4

Comorbidity relations with Heart Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 310)


3-Hydroxyacyl-Coa Dehydrogenase Deficiency Accessory Nerve Disease
Acquired Polycythemia Acquired Thrombocytopenia
Active Peptic Ulcer Disease Acute Anterolateral Myocardial Infarction
Acute Apical Periodontitis Acute Conjunctivitis
Acute Cor Pulmonale Acute Cystitis
Acute Inferolateral Myocardial Infarction Acute Kidney Failure
Acute Maxillary Sinusitis Acute Myocardial Infarction
Acute Myocarditis Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Adjustment Disorder
Age-Related Hearing Loss Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Allergic Urticaria
Alzheimer Disease Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Aspergillosis
Asthma Atrial Standstill 1
Atrioventricular Block Atrophic Gastritis
Bacteremia 2 Balanoposthitis
Basilar Artery Insufficiency Benign Essential Hypertension
Benign Hypertensive Renal Disease Benign Renovascular Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Blepharoconjunctivitis Bronchiectasis
Bronchitis Bronchopneumonia

Graphical network of the top 20 diseases related to Heart Disease:



Diseases related to Heart Disease

Symptoms & Phenotypes for Heart Disease

UMLS symptoms related to Heart Disease:


tremor, angina pectoris, edema, chest pain, syncope, equilibration disorder

Drugs & Therapeutics for Heart Disease

PubMed Health treatment related to Heart Disease: 63

Although many children who have congenital heart defects don't need treatment, some do. Doctors repair congenital heart defects with catheter procedures or surgery. Sometimes doctors combine catheter and surgical procedures to repair complex heart defects, which may involve several kinds of defects. The treatment your child receives depends on the type and severity of his or her heart defect. Other factors include your child's age, size, and general health. Some children who have complex congenital heart defects may need several catheter or surgical procedures over a period of years, or they may need to take medicines for years.

Drugs for Heart Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Pancrelipase Approved, Investigational Phase 4 53608-75-6
3
Pantoprazole Approved Phase 4 102625-70-7 4679
4
Zolpidem Approved Phase 4 82626-48-0 5732
5
Etanercept Approved, Investigational Phase 4 185243-69-0
6
Infliximab Approved Phase 4 170277-31-3
7
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Ipratropium Approved, Experimental Phase 4 60205-81-4, 22254-24-6 657309 43232
10
Zopiclone Approved Phase 4 43200-80-2 5735
11
Tirofiban Approved Phase 4 144494-65-5 60947
12
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
13
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
17
Vancomycin Approved Phase 4 1404-90-6 441141 14969
18
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
19
Ticagrelor Approved Phase 4 274693-27-5 9871419
20
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
21
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
22
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
23
Polyestradiol phosphate Approved Phase 4 28014-46-2
24
Deferiprone Approved Phase 4 30652-11-0 2972
25
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
26
Glyburide Approved Phase 4 10238-21-8 3488
27
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
28
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
29
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
30
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
31
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
32
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
33
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
34
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
35
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
36
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
37
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
38
Remifentanil Approved Phase 4 132875-61-7 60815
39
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
40
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
41
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
42
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
43
Fenofibrate Approved Phase 4 49562-28-9 3339
44
Doxazosin Approved Phase 4 74191-85-8 3157
45
Trandolapril Approved Phase 4 87679-37-6 5484727
46
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
47
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
48
Manidipine Approved, Investigational Phase 4 89226-50-6
49
Propranolol Approved, Investigational Phase 4 525-66-6 4946
50
Ticlopidine Approved Phase 4 55142-85-3 5472

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist Unknown status NCT00668824 Phase 4 Vasovist
2 A Strategy of Home Telehealth for Management of Congestive Heart Failure: STARTEL Unknown status NCT00247000 Phase 4
3 Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial Unknown status NCT01640639 Phase 4 Thalidomide;Placebo
4 Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure Unknown status NCT02087332 Phase 4 Prolonged release Torasemide (Britomar);Torasemide (Diuver)
5 A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients Unknown status NCT00690521 Phase 4 metolazone or hydrochlorothiazide
6 A Prospective, Randomized Trial Using a reproduciBLe volUmE-Measurement stratEGy in the surGical Reconstruction of the Ischemic Cardiomyopathic Heart Unknown status NCT00326690 Phase 4
7 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
8 Evaluation of Sildenafil for the Treatment of Moderate Congestive Heart Failure Unknown status NCT00793338 Phase 4 Sildenafil
9 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00374465 Phase 4 Verapamil;Carvedilol
10 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
11 Effects of add-on Aliskiren Treatment on Central and Peripheral Hemodynamics and Biomarkers in Patients With Chronic Congestive Heart Failure (NYHA Class II-IV) (First Year Project) Unknown status NCT01040494 Phase 4 Aliskiren;Placebo
12 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
13 Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy Unknown status NCT00348530 Phase 4 Verapamil
14 A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study of the Pre-Operative Effect of Sildenafil Citrate on Pulmonary Related Complications Following Cardiopulmonary Bypass in Children Undergoing Cardiac Surgical Repair. Unknown status NCT00350441 Phase 4 Sildenafil Citrate
15 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
16 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
17 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
18 Prevention of Heart Failure Events With Impedance Cardiography Testing (PREVENT-HF) Unknown status NCT00409916 Phase 4
19 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
20 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
21 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
22 Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications Unknown status NCT01682291 Phase 4
23 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
24 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
25 Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study Unknown status NCT00601679 Phase 4
26 The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function Unknown status NCT01825759 Phase 4 danshen dripping pill
27 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
28 Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial Unknown status NCT02015962 Phase 4 Intravenous potassium chloride;Oral potassium chloride
29 A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus Unknown status NCT03159559 Phase 4 Lipo-PGE1
30 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
31 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
32 Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial Unknown status NCT01612260 Phase 4 Shensong Yangxin capsule;placebo Capsule
33 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
34 Behavior and Exercise Versus Drug Treatment in Men With Nocturia Unknown status NCT00824200 Phase 4 tamsulosin (alpha-adrenergic antagonist medication);placebo
35 Safety and Efficacy of Angiotensin Receptor Blocker, Fimasartan, on Patients With Aortic Stenosis Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
36 Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure Unknown status NCT02686866 Phase 4
37 Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure Unknown status NCT03255044 Phase 4 Atorvastatin;Rosuvastatin
38 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
39 Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism Unknown status NCT02316743 Phase 4 Levothyroxine supplementation
40 Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm Unknown status NCT02046044 Phase 4 Digoxin;Ivabradine
41 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
42 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
43 Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI Unknown status NCT02787317 Phase 4 bivalirudin;Heparin
44 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
45 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
46 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
47 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study) Unknown status NCT01021930 Phase 4
48 Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
49 Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI Unknown status NCT03006835 Phase 4 Clopidogrel
50 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4

Search NIH Clinical Center for Heart Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylsalicylic acid
Atenolol
Atenolol
Atorvastatin
benazepril
Benazepril
Benazepril hydrochloride
Bendroflumethiazide
benzthiazide
Bisoprolol
Bisoprolol
Bisoprolol Fumarate
Bumetanide
candesartan
candesartan cilexetil
Captopril
Captopril
carvedilol
carvedilol phosphate
Chlorothiazide
Chlorothiazide sodium
Chlorthalidone
coenzyme Q10
cyclothiazide
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Dobutamine
Enalapril
Enalapril Maleate
Enalaprilat
Enalaprilat
eprosartan
Eprosartan mesylate
esmolol
Esmolol hydrochloride
Etacrynic acid
Ethacrynate Sodium
Ethacrynic Acid
Fenoldopam
Fenoldopam Mesylate
Fluvastatin
Fosinopril
Fosinopril
Fosinopril Sodium
Furosemide
Growth Hormone
Hydralazine
Hydralazine
Hydralazine Hydrochloride
Hydrochlorothiazide
Hydroflumethiazide
Inamrinone
inamrinone lactate
Indapamide
Isosorbide
Isosorbide dinitrate
Isosorbide Dinitrate
Isosorbide Mononitrate
Labetalol
Labetalol hydrochloride
Lisinopril
Losartan
Losartan
Losartan Potassium
Methyclothiazide
Metolazone
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Milrinone
Milrinone Lactate
moexipril
Moexipril hydrochloride
Nadolol
Nitroglycerin
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
Polythiazide
Propranolol
Propranolol Hydrochloride
quinapril
Quinapril hydrochloride
quinethazone
Ramipril
Ramipril
Rosuvastatin
Sodium Nitroprusside
somatrem
Somatropin
SOMATROPIN (RECOMBINANT DNA ORIGIN)
Spironolactone
SPIRONOLACTONE PWDR
telmisartan
Telmisartan
Timolol
Timolol Hemihydrate
Timolol Maleate
torsemide
trandolapril
Trandolapril
Trichlormethiazide
valsartan

Cochrane evidence based reviews: heart diseases

Genetic Tests for Heart Disease

Genetic tests related to Heart Disease:

# Genetic test Affiliating Genes
1 Congenital Heart Disease 29
2 Congenital Heart Defects 29

Anatomical Context for Heart Disease

MalaCards organs/tissues related to Heart Disease:

41
Heart, Testes, Endothelial, Kidney, Lung, Brain, Bone

Publications for Heart Disease

Articles related to Heart Disease:

(show top 50) (show all 61931)
# Title Authors PMID Year
1
Arrhythmias in Congenital Heart Disease. 38 17
31378336 2019
2
MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. 38 88
20837903 2010
3
The Electrocardiogram: Still a Useful Tool in the Primary Care Office. 17
31378324 2019
4
Cardiac Implantable Electronic Device Therapy: Permanent Pacemakers, Implantable Cardioverter Defibrillators, and Cardiac Resynchronization Devices. 17
31378335 2019
5
Cross-sectional imaging of congenital pulmonary artery anomalies. 17
31175525 2019
6
Current research trends and challenges in tissue engineering for mending broken hearts. 17
31103607 2019
7
Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. 17
31162568 2019
8
Comparative Analysis of Myocardial Protection with HTK Solution and Hypothermic Hyperkalemic Blood Solution in the Correction of Acyanogenic Congenital Cardiopathies - A Randomized Study. 17
31310464 2019
9
A randomized controlled trial on the impact of moderate-intensity continuous aerobic exercise on the depression status of middle-aged patients with congestive heart failure. 17
31027110 2019
10
Significance of L-carnitine in internal medicine. 17
31090382 2019
11
MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. 88
20837890 2010
12
Effects of myosin heavy chain manipulation in experimental heart failure. 9 38
19854200 2010
13
Myostatin: an overlooked player in heart failure? 9 38
20348549 2010
14
Heart failure and pulmonary hypertension. 9 38
20347789 2010
15
[Novel GATA4 mutations identified in patients with congenital heart disease]. 9 38
20450724 2010
16
Should erythropoietin treatment in chronic heart failure be haemoglobin targeted? 9 38
20156936 2010
17
Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. 9 38
20211335 2010
18
Novel treatment strategy with direct renin inhibition against heart failure. 9 38
20228725 2010
19
Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure. 9 38
20233990 2010
20
NKX2.5 mutations in patients with non-syndromic congenital heart disease. 9 38
19073351 2010
21
Erythropoietin, iron, or both in heart failure: FAIR-HF in perspective. 9 38
20083619 2010
22
Circulating levels of stress associated peptide Urocortin in heart failure patients. 9 38
19961889 2010
23
Exercise training reduces circulating adiponectin levels in patients with chronic heart failure. 9 38
19656085 2010
24
[Polymorphism of eNOS and iNOS Genes and Chronic Heart Failure in Patients With Ischemic Heart Disease]. 9 38
20459417 2010
25
Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. 9 38
19945058 2010
26
Myostatin: Regulator of muscle wasting in heart failure and treatment target for cardiac cachexia. 9 38
20065169 2010
27
Too much, too little, or just right?: untangling endogenous erythropoietin in heart failure. 9 38
20048201 2010
28
Endogenous erythropoietin and outcome in heart failure. 9 38
20048213 2010
29
Phosphodiesterase inhibition in heart failure. 9 38
19096931 2009
30
Carperitide and adiponectin--how are they connected each other to benefit acute decompensated heart failure? 9 38
19940369 2009
31
Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. 9 38
19666068 2009
32
Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. 9 38
19713201 2009
33
Ghrelin resistance in heart failure or why failing cardiomyocytes do not produce ghrelin: the same problem? 9 38
19875414 2009
34
Beta-2 adrenergic receptor gene polymorphisms Gln27Glu, Arg16Gly in patients with heart failure. 9 38
19886995 2009
35
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. 9 38
19919976 2009
36
Beta-adrenergic blockers for chronic heart failure. 9 38
19829179 2009
37
Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. 9 38
19717736 2009
38
B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study. 9 38
19636481 2009
39
Newer biomarkers in heart failure. 9 38
19631181 2009
40
ST2 and adrenomedullin in heart failure. 9 38
19631176 2009
41
Growth-differentiation factor-15 in heart failure. 9 38
19631178 2009
42
Myoglobin concentration in skeletal muscle fibers of chronic heart failure patients. 9 38
19661455 2009
43
C-type natriuretic peptide production by the human kidney is blunted in chronic heart failure. 9 38
19450232 2009
44
Angiotensin receptor blocker therapy for heart failure patients: is combination treatment a feasible prospect? 9 38
19743497 2009
45
Point-of-care testing for cardiac markers in acute coronary syndromes and heart failure. 9 38
19840688 2009
46
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. 9 38
19255799 2009
47
Plasma urocortin 1 in human heart failure. 9 38
19808377 2009
48
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. 9 38
19700132 2009
49
The use of beta3-adrenergic receptor agonists in the treatment of heart failure. 9 38
19705338 2009
50
Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. 88
19514064 2009